Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Hepatology. 2019 Jun 24;70(3):995–1010. doi: 10.1002/hep.30691

Figure 8. Treatment with the hPXR antagonist SPA70 protects the hPXR/hCYP3A4 humanized mice from HS-induced hepatic injury.

Figure 8.

(A) Schematic representation of the SPA70 pre-treatment model. Mice were intraperitoneally injected with VEH, RIF (10 mg/kg) and SPA70 (150 mg/kg) individually or in combination for 3 days before receiving the sham surgery or HS/R. (B) The hepatic mRNA expression of CYP3A4 was measured by qRT-PCR. (C) Liver histology was analyzed by H&E staining. Shown on the right are quantification of necrotic areas and Suzuki scores. (D) Serum levels of ALT. (E and F) The hepatic levels of 4-HNE (arrowheads indicated the positive staining) (E) and 8-OHdG (F) were measured by immunostaining and immunofluorescence, respectively. (G) The hepatic mRNA expression of Atf3 and Chop was measured by qRT-PCR. Bars are 100 μm. n=4~5 for each group. *, p < 0.05; **, p < 0.01, the comparisons are labeled.